Compare Adaptive Biotechnologies Corp (ADPT) vs Nerdwallet Inc (NRDS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Adaptive Biotechnologies Corp vs Nerdwallet Inc — how do they compare? Adaptive Biotechnologies Corp trades at $25.12 (market cap $4.04B), while Nerdwallet Inc trades at $9.51 (market cap $625.17M). The key difference: Adaptive Biotechnologies Corp is far larger — about 6.5× Nerdwallet Inc's market cap, and Adaptive Biotechnologies Corp is trading nearer its 52-week high, Nerdwallet Inc nearer its low. Which is the better fit depends on your goals.
| ADPT | NRDS | |
|---|---|---|
Market Cap | $4.04B | $625.17M |
Sector | Health | Financials |
52-Week High | $25.45 | $15.93 |
52-Week Low | $12.30 | $7.58 |
Enterprise Value | $4.10B | $539.47M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADPT trades at $25.45, up 2.09% today, near its 52-week high. The stock shows bullish technical signals with support at $25 and resistance at $26. Revenue growth accelerated to $277M in 2025, though net losses persist. Recent news highlights a strategic separation of its MRD and Immune Medicine businesses, aiming to unlock value.
Outlook is cautiously optimistic with 65% analyst buy ratings and a $25.50 price target. Key opportunities include MRD segment profitability and separation benefits, while risks involve sustained losses, competitive pressures, and execution challenges in the business split.
NRDS trades at $9.76, down 0.41% today, with a bullish technical signal from moving averages but mixed oscillators. The company reported Q2 2026 revenue of $197 million, up 6% year-over-year, though EPS missed estimates. Valuation ratios appear attractive with a P/E of 10.87 and P/S of 0.81, while profitability metrics like an 18.16% ROE and 93.5% gross margin remain strong. Recent news highlights analyst optimism for a 27.9% upside potential.
The outlook is positive due to solid fundamentals and growth in personal loans and deposit accounts, offsetting SEO pressures. Risks include execution in shifting business models and competitive threats. With 66.7% of analysts rating it Buy and a consensus bullish stance, the stock presents a growth opportunity amid manageable risks.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Adaptive Biotechnologies Corp
Adaptive Biotechnologies Corp is a commercial-stage company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease in patients with select blood cancers.
Read more on ADPT →About Nerdwallet Inc
Nerdwallet Inc is a free tool to find you the best credit cards, cd rates, savings, checking accounts, scholarships, healthcare and airlines.
Read more on NRDS →
